Sangamo Therapeutics(SGMO) - 2025 Q4 - Earnings Call Transcript

Sangamo Therapeutics (NasdaqCM:SGMO) Q4 2025 Earnings call March 30, 2026 04:30 PM ET Company ParticipantsCassie Yuan - Biotechnology Equity Research AssociateJames Heaney - Equity Research SVPLouise Wilkie - Head of Investor Relations and Corporate CommunicationsLuis Santos - Senior Equity Research AssociateNathalie Dubois-Stringfellow - Chief Development OfficerSandy Macrae - CEOOperatorGood afternoon, and welcome to the Sangamo Therapeutics fourth quarter and full year 2025 teleconference call. Please be ...